Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

Kathleen Keegan, Cong Li, Zhihong Li, Ji Ma, Mark Ragains, Suzanne Coberly, David Hollenback, John Eksterowicz, Lingming Liang, Margaret Weidner, Justin Huard, Xianghong Wang, Grace Alba, Jessica Orf, Mei-Chu Lo, Sharon Zhao, Rachel Ngo, Ada Chen, Lily Liu, Tim Carlson, Christophe Quéva, Lawrence R. McGee, Julio Medina, Alexander Kamb, Dineli Wickramasinghe, and Kang Dai

Abstract

Acute myeloid leukemia (AML) remains a serious unmet medical need. Despite high remission rates with chemotherapy standard-of-care treatment, the disease eventually relapses in a major proportion of patients. Activating Fms-like tyrosine kinase 3 (FLT3) mutations are found in approximately 30% of patients with AML. Targeting FLT3 receptor tyrosine kinase has shown encouraging results in treating FLT3-mutated AML. Responses, however, are not sustained and acquired resistance has been a clinical challenge. Treatment options to overcome resistance are currently the focus of research. We report here the preclinical evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib). CDK4 is a cyclin D–dependent kinase that plays an essential central role in regulating cell proliferation in response to external growth signals. A critical role of the CDK4–RB pathway in cancer development has been well established. CDK4-specific inhibitors are being developed for treating RB-positive cancer. AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clinical responses.

Mol Cancer Ther; 13(4); 1–10. ©2014 AACR.

Introduction

Acute myeloid leukemia (AML) represents a significant unmet medical need. It is a hematologic malignancy characterized by uncontrolled proliferation of the hematopoietic progenitor cells of myeloid lineage. The current standard of care is chemotherapy with and without allogeneic stem cell transplantation. Induction chemotherapy is successful in 65% of all patients with AML. Using chemotherapy as consolidation, up to 50% of patients that receive consolidation go into long-term remission. The actual chance of long-term remission depends on specific prognostic factors such as age, chromosomal aberrations, and molecular changes. The relative 5-year survival rate is 24% in patients diagnosed with AML (1). More efficacious and safer therapeutics are being developed and tested in clinical trials.

FLT3 (Fms-like tyrosine kinase 3) is a well-recognized drug target for treating AML. Activating mutations in FLT3 are found in approximately 30% of patients with AML (2–4). The majority of the activating mutations are internal tandem duplications (ITD) in the juxtamembrane region. Numerous FLT3 inhibitors have entered clinical studies and shown initial clinical responses. However, the responses are transient and resistance develops rapidly (5, 6). The major resistance mechanism seems to be acquisition of secondary mutations in FLT3, which interfere with the ability of small-molecule inhibitors to bind to FLT3 (4, 5). One strategy to overcome resistance to FLT3 inhibitors in the clinic is to combine them with chemotherapy despite the recognition that chemotherapy is poorly tolerated (6, 7).

Cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) are two functionally indistinguishable cyclin D–dependent kinases. As a key downstream effector of growth factor activation, CDK4 promotes G1–S transition of the cell cycle by phosphorylating the retinoblastoma protein (RB), a tumor-suppressor protein. A large body of evidence supports important involvement of the p16INK4a–CDK4–RB axis in cancer development (8–12). RB negatively regulates the cell cycle at G1 by sequestering E2F proteins.
that are required for initiation of S phase. p16\textsuperscript{INK4a} is a member of the INK4 family of CDK4 cellular inhibitors (10–13) and a tumor suppressor. The genes for RB and p16\textsuperscript{INK4a} are frequently deleted or silenced in various types of cancer. Although mutations in RB and p16\textsuperscript{INK4a} are rare in patients with AML, p15\textsuperscript{INK4b}, another member of the INK4 family, has been reported to be downregulated in up to 60% of patients with AML (14, 15), indicating an important role of CDK4 in AML. Recently, a selective CDK4 inhibitor PD 0332991 has entered clinical trials and showed promising anticancer efficacy in patients with advanced breast cancer (16, 17). Anticancerr activity of PD 0332991 has also been reported in clinical and preclinical studies of other cancer types, including AML (18–21). Here, we report the preclinical evaluation of a FLT3/CDK4 dual kinase inhibitor AMG 925. We believe that combined inhibition of two essential kinases by AMG 925 has potential to reduce development of drug resistance in patients with AML.

Materials and Methods

Compounds

AMG 925 (2-(2-((9-(trans-4-methylcyclohexyl)-9H-pyrido[4,3',4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-oxoethanol) was synthesized at Amgen. PD 0332991 and sorafenib were purchased from AdooQ BioScience.

Cell lines

MOLM13 and Mv4-11 were obtained from the DSMZ German Collection of Microorganisms and Cell Cultures. MOLM13-Luc cells were constructed by transduction of MOLM13 cells with the pLV218G luciferin/lentivirus, which expresses luciferase under the murine EF1\textalpha promoter. Sorafenib-resistant MOLM13 (MOLM13sr) and Mv4-11 (Mv4-11sr) were isolated by passaging the cells in growth medium containing increasing concentrations of sorafenib (1–1,000 nmol/L). RNA was isolated from independent clones and sequenced to identify FLT3 kinase domain mutations, D835Y in Mv4-11. The other cell lines used in this study were purchased from American Type Culture Collection. D835V in Mv4-11. The other cell lines used in this study were purchased from American Type Culture Collection. Growth conditions recommended by the providers were followed. All of the cell lines were authenticated by short tandem repeat DNA profiling; MDA-MB-435, MDA-MB-436, and MDA-MB-468 were by Genetica DNA Laboratories; and the rest by DDC Medical.

Kinases

CDK4/cyclin D1, CDK6/cyclin D1, CDK1/Cyclin B, and CDK2/Cyclin A were purchased from Cell Signaling Technology. For the kinase assays, RB fragment (amino acids 773–928) and histone H1 (Millipore) were used as substrate for CDK4/6 and CDK1/2, respectively. [\textsuperscript{32P}]ATP was from PerkinElmer. The assays were performed in 96-well filter plates (MSDVN6B50; Millipore) with a final volume of 100 \mu L, containing 1 \mu g RB, 25 ng CDK4/cyclin D1, 25 \mu mol/L ATP, 1 \mu Ci [\textsuperscript{32P}]ATP, and the test compound in kinase reaction buffer (20 mmol/L Tris-HCl, pH 7.4, 10 mmol/L MgCl\textsubscript{2}, 5 mmol/L \beta-glycerophosphate, 1 mmol/L dithiothreitol (DTT), and 0.1% bovine serum albumin). The reaction mixes were incubated at room temperature for 1 hour and terminated with 20% trichloroacetic acid (TCA). Wells were washed with 10% TCA, let dry, and processed for scintillation counting with TopCount (PerkinElmer). FLT3 kinase assay was performed using a time-resolved fluorescence resonance energy transfer assay. The FLT3 enzyme (glutathione S-transferase–fused human FLT3 cytoplasmic domain, amino acids 564–993) was from Carma Biosciences. An ULight-labeled synthetic peptide (ULight-JAK1; PerkinElmer) derived from human Janus kinase 1 (amino acids 1015–1027) was used as the phosphoacceptor substrate. The FLT3 kinase reaction was conducted in a 384-well white OptiPlate (PerkinElmer) in a total volume of 20 \mu L. The reaction mixture contained 50 nmol/L ULight-JAK1, 116 \mu mol/L ATP (equal to K\textsubscript{m}), 0.5 nmol/L FLT3, and serially diluted test compounds in a reaction buffer of 50 mmol/L Heps, pH 7.6, 1 mmol/L EGTA, 10 mmol/L MgCl\textsubscript{2}, 2 mmol/L DTT, and 0.005% Tween 20. The reaction was allowed to proceed for 1 hour at room temperature and stopped by adding 20 \mu L of 20 mmol/L EDTA and 4 nmol/L LANCE Eu-W1024 anti-phosphorytrosine antibody in LANCE detection buffer (PerkinElmer). The plates were incubated at room temperature for 2 hours after addition of detection reagents and were then read on an Envision multimode reader (PerkinElmer). Fluorescence signals were measured at 615 nm (8.5-nm bandwidth) and 665 nm (7.5-nm bandwidth) with a 60-\mu s delay after excitation at 320 nm (75-nm bandwidth). The signal ratio at 665/615 nm was used in all data analyses.

Cell growth, apoptosis, and cell cycle

Cell growth was measured by a DNA synthesis assay. Cells were seeded in a 96-well Cytostar T plate (GE Healthcare Biosciences) at a density of 5 \times 10\textsuperscript{4} cells/well in a total volume of 160 \mu L. Test compounds were serially diluted into the plate (20 \mu L/well) and 20 \mu L/0.1 \mu Ci of [\textsuperscript{14}C]-Thymidine (GE Healthcare Biosciences) added to each well. Isotope incorporation was determined using a \beta plate counter (Wallac) after further 72-hour incubation. Apoptosis was assayed by using the Vybrant Apoptosis Assay Kit#9 (Invitrogen; Cat# V35113) following the manufacturer’s protocol. Briefly, cells were seeded into a 6-well plate at 5 \times 10\textsuperscript{5} cells per well and treated with compounds for 24 hours. The cells were then stained with reagents provided in the kit and analyzed by flow cytometry. The Sytox Green fluorescence versus aliphycocyanin fluorescence dot plot shows resolution of live, apoptotic, and dead cells, which were quantified using the Flowjo software. The cell-cycle analysis was done by treating the cells with AMG 925 for 24 hours followed by using the CycleTest Kit (BD Biosciences) following manufacturer’s instructions. Ten thousand events were acquired and the
proportions of cells in each cycle phase were calculated using the ModFit software.

**P-FLT3, P-STAT5, and P-RB**

Phospho-FLT3 (P-FLT3) was determined by immunoprecipitation and Western blotting (IP-WB). A total of $2 \times 10^5$ cells/mL were treated with compounds for 1 hour. Cell lysates were prepared in RIBA cell lysis buffer (G-Biosciences; Cat#786-489) incubated with an anti-FLT3 antibody (Cell Signaling Technology; Cat# 3462) at 4°C overnight. Immunocomplexes were recovered with the Protein G Kit (Sigma; Cat# 087K4817) and subjected to WB with anti-phosphotyrosine 4G10 (Millipore; Cat# 05-1050) for P-FLT3 or an anti-FLT3 antibody (R&D Systems; Cat# BAF812) for total FLT3 (T-FLT3). Protein bands were visualized using enhanced chemiluminescence reagents (GE Healthcare Bio-Sciences; Cat# RPN2106) and analyzed with the ImageJ software (NIH). Meso Scale Discovery (MSD) assays were used to determine cellular levels of phospho-STAT5 (P-STAT5) and phospho-RB (P-RB). A total of $1 \times 10^4$ cells/well in 96-well plates were incubated with dilutions of compounds. Cell lysates were harvested 1 or 24 hours after addition of compounds for determination of P-STAT5 and P-RB, respectively, using kits from Meso Scale Discovery (Cat# K150IGD-1 for P-STAT5 and Cat# K150ITD-1 for P-RB).

To determine P-STAT5 or P-RB in xenograft tumor samples, tumors were allowed to grow to 200 to 250 mm$^3$ before administration of AMG 925 via oral gavages. The tumor samples were dissected and snap frozen at different time points after dosing, and the lysates prepared and assayed for levels of P-STAT5 and P-RB similarly as for cultured cells.

**MOLM13 xenograft tumor model**

CrTac:NCR-Foxn1$^{tm}$ (NCR) nude mice were treated with an intraperitoneal (i.p.) injection of 100 μL of anti-asialo GM (WAKO Chemicals) antibody to abolish natural killer activity and allow for enhanced growth of subsequently inoculated tumor cells. The following day, 7.5 million MOLM13 tumor cells in PBS were formulated as a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of the mice. Tumors were measured with PRO-MAX electronic digital caliper (Japan Micrometer Mfg. Co. LTD) and the mice were weighed every other day before each tumor measurement. Tumor volumes were calculated as follows: tumor volume (mm$^3$) = $(W^2 \times L)/2$ in which width ($W$) is defined as the smaller of the two measurements and length ($L$) is defined as the larger of the two measurements.

**MOLM13-Luc systemic tumor model**

MOLM13-Luc cells stably expressing luciferase were injected intravenously (i.v.) into NOD/SCID IL-2Rγ$^{-/-}$ (NSG) mice. After 6 days, mice were injected with an i.p. injection of D-luciferin, tissues removed, and imaged using an IVIS imager. MOLM13-Luc cells localized to the spleen and the bone marrow of the sternum and hind limbs. At 13 days after injection, tumor cells were more widespread to the peripheral blood, spleen, lung, ovaries, and calvaria. For efficacy evaluation of AMG 925, $5 \times 10^4$ MOLM13-Luc cells in PBS were inoculated via i.v. injection in tail vein. The cells were allowed to grow for 6 days and randomized for treatment using imaging with a Xenogen IVIS 200 imager (PerkinElmer). Before imaging, mice were given an i.p. injection of 150 mg/kg Firefly D-luciferin (Caliper Life Sciences) and dorsal and ventral images were captured. Tumor burden was quantified using Living Image 2.5 software for regions of interest (ROI): total body (dorsal and ventral). Mice ($n = 60$) were sorted from low to high by drawing ROIs over the dorsal and ventral images and taking the sum of these images (whole-body bioluminescence imaging). The bottom 5 and top 5 animals in the sort were excluded from the study. The remaining mice were randomly assigned to therapeutic groups to achieve five groups of ($n = 10$) with equivalent whole-body tumor burden. Treatments were initiated on day 7 and continued for 10 consecutive days. Twice daily doses were administered 6 hours apart. After completion of the treatments, mice were monitored for either development of hind limb paralysis (HLP) that resulted from disease progression and $>20\%$ body weight loss. Mice were humanely sacrificed using CO2 asphyxiation and cervical dislocation in accordance with Amgen Institutional Animal Care and Use Committee (IACUC) criteria.

**Colo205 xenograft tumor model**

$2 \times 10^6$ cells were inoculated on the flank of NCR nude mice and allowed to grow for 13 days. Mice were then dosed twice a day by oral administration 6 hours apart with 12.5, 25, 37.5, and 50 mg/kg of AMG 925 formulated in 2% hydroxypropyl methylcellulose/1% Tween 80 for 10 consecutive days.

**Pharmacokinetics and plasma concentration**

Animals were orally dosed with AMG 925 and plasma samples were collected at time points after dosing. Concentrations of AMG 925 in the plasma were determined with a multiple reaction monitoring method on a triple quadrupole mass spectrometer coupled with high-pressure liquid chromatography system. Unbound AMG 925 concentrations were calculated based on protein binding of the compound.

**Immunohistochemistry**

Femur samples from 3 mice in each of the treatment groups were taken at 2 and 18 hours after the last dose and processed for cutting sections for immunohistochemistry (IHC) staining. Sections were deparaffinized and then heated in DIVA Decloaker solution for P-RB (Biocare) or BORG Decloaker for P-STAT5 (Biocare) for 1 hour for antigen retrieval. Remaining IHC steps were performed at room temperature in a DAKO Autostainer. Sections were incubated for 10 minutes with Peroxidized 1 (Biocare) to block endogenous peroxidase, followed by incubation for 10 minutes with Background Sniper for P-RB.
AMG 925 is a potent, selective, and orally available FLT3/CDK4 dual inhibitor

AMG 925 was discovered by high throughput screening and lead optimization. In vitro activities of AMG 925 are summarized in Table 1 and Fig. 1. AMG 925 potently inhibited FLT3, CDK4, and CDK6 in kinase assays with IC₅₀ in single-digit nanomolar range. The selectivity of AMG 925 for CDK4 and FLT3 against CDK1, in which inhibition is highly cytotoxic, was >500-fold. A fair overall kinase selectivity of AMG 925 was as determined by KinomScan against a panel of 442 various kinases (Supplementary Table S1). Cellular selectivity (on-target vs. off-target activity) of AMG 925 was about 50-fold as evaluated by comparison of its growth-inhibiting activity in RB-positive (RB⁺) and RB-negative (RB⁻) non-AML cancer cell lines (Table 1).

AMG 925 potently inhibited growth of AML cell lines MOLM13 (FLT3-ITD; IC₅₀ = 0.019 μmol/L) and Mv4-11 (FLT3-ITD; IC₅₀ = 0.018 μmol/L). To determine that AMG 925 inhibited growth of MOLM13 and Mv4-11 cells through FLT3, P-FLT3 and P-STAT5, direct substrates of FLT3, were measured as specific pharmacodynamic markers. In addition, apoptosis, a phenotype characteristic of inhibition of FLT3 in sensitive AML cells, was examined. As shown in Table 1, AMG 925 potently inhibited P-STAT5 in AML cell lines MOLM13 (FLT3-ITD) and Mv4-11 (FLT3-ITD) with IC₅₀ values comparable with those for kinase and growth inhibition. In Fig. 1B, AMG 925 induced apoptosis in MOLM13 in a dose-dependent manner, but not in the FLT3-independent U937, indicating a specific inhibition of FLT3 in MOLM13. Furthermore, the apoptosis correlated with inhibition of P-FLT3 and P-STAT5 in treated cells. Similar effects by AMG 925 were observed in Mv4-11 cells (data not shown). To demonstrate inhibition of CDK4 by AMG 925 in cells, cell-cycle analysis was carried. As shown in Fig. 1C, AMG

<table>
<thead>
<tr>
<th>Kinase assays IC₅₀, μmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3</td>
</tr>
<tr>
<td>CDK4</td>
</tr>
<tr>
<td>CDK6</td>
</tr>
<tr>
<td>CDK1</td>
</tr>
<tr>
<td>CDK2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growth inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOLM13 (FLT3-ITD)</td>
</tr>
<tr>
<td>Mv4-11 (FLT3-ITD)</td>
</tr>
<tr>
<td>U937 (FLT3-WT)</td>
</tr>
<tr>
<td>THP1 (FLT3-WT)</td>
</tr>
<tr>
<td>MOLM13sr (FLT3-ITD/D835Y)</td>
</tr>
<tr>
<td>Mv4-11sr (FLT3-ITD/D835V)</td>
</tr>
<tr>
<td>Colo205 (RB⁺)</td>
</tr>
<tr>
<td>MDA-MB-435 (RB⁺)</td>
</tr>
<tr>
<td>MDA-MB-468 (RB⁺)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cellular assays IC₅₀, μmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth inhibition</td>
</tr>
<tr>
<td>MOLM13</td>
</tr>
<tr>
<td>Colo205</td>
</tr>
</tbody>
</table>

NOTE: Relevant genotypes of cell lines are shown in parentheses. Experiments to determine IC₅₀ were repeated at least 3 times. IC₅₀ values indicated as mean ± SD.

Abbreviation: Mv4-11sr, sorafenib-resistant Mv4-11.
925 induced G₁ arrest in RB⁺ MOLM13, U937, and Colo205. In contrast, AMG 925 did not cause G₁ arrest in RB⁻ MDA-MB-468, which is consistent with the growth inhibition potency of AMG 925 in these cell lines (Table 1).

Pharmacokinetic analysis showed that AMG 925 was orally available with a half-life appropriate for twice daily dosing in preclinical animals (Supplementary Fig. S1).

**AMG 925 inhibits signaling of FLT3-ITD/D835 mutants**

Two sorafenib-resistant AML cell lines MOLM13sr and Mv4-11sr were isolated as described in Materials and Methods. The parental cells MOLM13 and Mv4-11 acquired FLT3-D835Y and Mv4-11sr FLT3-D835V, respectively, during isolation for resistance to sorafenib. We found that AMG 925 inhibited growth of both sorafenib-resistant AML cell lines with potency comparable with those of the parental cell lines MOLM13 and Mv4-11 (Table 1). Growth inhibition of MOLM13sr and Mv4-11sr by AMG 925 is believed to be primarily through FLT3, which is supported by potent inhibition of P-STAT5 by AMG 925 in the cells (Table 1). This is also supported by dose-dependent induction of apoptosis by AMG 925 in the MOLM13sr cells, which was correlated with inhibition of P-FLT3 and P-STAT5 (Fig. 1B). Sorafenib, however, caused only background level of apoptosis and was much less potent in inhibiting P-FLT3 or P-STAT5 than AMG 925. Similar effects were observed in Mv4-11sr (our unpublished observations).

**AMG 925 inhibits growth of subcutaneous MOLM13 xenograft tumors**

MOLM13 tumor–bearing mice were dosed twice daily by oral administration 6 hours apart with 12.5, 25, or 37.5
mg/kg AMG 925. Tumors were then harvested 3, 9, 12, and 24 hours after the first dose, and analyzed for levels of P-STAT5 and P-RB. Maximum inhibition of P-STAT5 and P-RB was achieved at 6 and 12 hours respectively at the 37.5 mg/kg dose of AMG 925 (Fig. 2A, top and bottom). Interestingly, a rebound of P-STAT5 at 24 hours was observed, possibly as a result of compensational feedback. The pharmacodynamic responses of P-STAT5 and P-RB inhibition correlated with plasma concentrations of AMG 925 (Fig. 2A, top and bottom).

To determine antitumor efficacy of AMG 925, tumor-bearing mice were orally dosed twice daily with AMG 925. Dose-dependent inhibition of tumor growth was observed with the maximum inhibition after treatment with 37.5 mg/kg AMG 925 (tumor growth inhibition, TGI = 96%; P < 0.0001; Fig. 2B, top). Taken together with the pharmacodynamic data, this suggests that maximal efficacy in this model was achieved with greater than 80% inhibition of P-STAT5 and greater than 90% inhibition of P-RB for at least 12 hours. No differences in body weight were observed (Fig. 2B, bottom). An ED₅₀ of 9.2 mg/kg (95% confidence interval, CI, 5.8–14.4) was calculated using individual tumor volumes on day 15.

**AMG 925 inhibits growth of systemic MOLM13-Luc xenograft tumors**

To more closely mimic human AML, a MOLM13 systemic tumor model was developed (see Materials and Methods). Mice injected with MOLM13-Luc cells were dosed with AMG 925 twice daily for 10 consecutive days. AMG 925 demonstrated dose-dependent antitumor activity with calculated TGI of 99.7%, 97%, and 71% for the 37.5, 25, and 12.5 mg/kg dose groups, respectively (Fig. 3A). An ED₅₀ of 11 mg/kg (95% CI, 9.7–12.3) was calculated, which was consistent with the ED₅₀ determined in the MOLM13 subcutaneous tumor model. Figure 3B represents images taken at the end of the dosing period showing that tumor cells in mice (colored) were greatly reduced compared with vehicle control. No effects on body weight were observed during the dosing period. Time to moribund sacrifice was also measured for the systemic MOLM13-Luc tumor model. After completion of
the 10-day dosing period, mice were monitored for signs of morbidity and sacrificed according to IACUC guidance. The mean time to moribund sacrifice was 21, 24, and 26 days for the 12.5, 25, and 37.5 mg/kg doses, respectively, compared with 17.4 days for the vehicle-treated mice (P < 0.05; Fig. 3C). After cessation of AMG 925 treatment, all mice eventually succumbed to disease progression. The terminal symptoms of mice in all treatment groups were similar to those in the vehicle group. MOLM13-Luc cells were detectably further spread from the initial major sites of spleen and the bone marrow of sternum and hind limbs to the peripheral blood, lung, ovaries, and calvaria (Fig. 3B). HLP, which apparently resulted from severe infiltration of the AML cells in the bone of hind limbs, was closely observed as the beginning of terminal stage of the disease. As soon as the mice showed HLP and/or 20% weight loss, they were humanely sacrificed.

To correlate the antitumor activity of AMG 925 with pharmacodynamic activity in this systemic model, the effect of AMG 925 on P-STAT5 and P-RB in the bone marrow-engranted tumor cells was assessed in a separate pharmacokinetic/pharmacodynamic analysis. Mice were injected with MOLM13-Luc cells and 14 days after injection, mice were administered two doses of AMG 925 6 hours apart. Femurs were harvested 8 and 24 hours after the first dose administration and processed for IHC staining for P-STAT5 or P-RB and positive nuclei counted (see Supplementary Fig. S2 for quantitative data).

Figure 3. Activity of AMG 925 in systemic MOLM13-Luc xenograft tumor model. A, NSG mice engrafted with MOLM13-Luc tumors were treated with 12.5, 25, or 37.5 mg/kg (mpk) AMG 925. Tumor burden was determined by quantification of total body bioluminescence. Mice were injected with 150 mpk Firefly D-luciferin before imaging. Using unpaired t test and two-tailed P values to determine significance, all AMG 925 treatment groups were shown to be significant as compared with vehicle group. All comparisons with vehicle have a P < 0.001. B, bioluminescence images of mice at the end of dosing period. C, all AMG 925 treatments significantly increased time to humane sacrifice relative to vehicle. Mice that were moribund, showed signs of HLP, or lost 20% of starting body weight were euthanized and plotted. D, femurs of mice treated similarly as in A were harvested at 8 or 24 hours after the initial dose administration and processed for IHC staining for P-STAT5 or P-RB and positive nuclei counted (see Supplementary Fig. S2 for quantitative data).

TGI by AMG 925 in Colo205 xenografts

To demonstrate that the CDK4/6 inhibitory activity of AMG 925 would lead to TGI, we used the RB-positive
Colo205 colon adenocarcinoma xenograft model in which growth was independent of FLT3 activity. Oral administration of AMG 925 resulted in dose-dependent antitumor activity with a TGI of 97% at the highest dose tested (50 mg/kg, twice daily; Fig. 4). The ED50 was calculated as 37 mg/kg (95% CI, 26–51). Body weight loss was not observed. The TGI correlated with inhibitory activity of AMG 925 primarily acts through reducing frequency and/or expansion of mutants resistant to FLT3-inhibiting activity of the compound. Consistently, we have tried but failed to isolate AMG 925–resistant FLT3 mutations in MOLM13 and Mv4-11 under conditions that we used to isolate sorafenib-resistant mutations (our unpublished data). A potential advantage of AMG 925 over combining a FLT3 inhibitor with chemotherapy is that the CDK4-inhibiting activity of AMG 925 overcomes resistance by bypassing or compensatory mechanisms, e.g., loss of RB and increase in Cyclin E1 expression (20, 25; our unpublished observations). AMG 925 inhibits both FLT3 and CDK4 potentially offering a more effective treatment for AML than single kinase selective inhibitors. CDK4 activity is downstream of FLT3 signaling and is required for cell proliferative response to FLT3 activation. However, the function of the two kinases is not fully overlapping. As a central player in cell-cycle regulation, CDK4 mediates signaling from other upstream growth factors as demonstrated by G1 arrest of FLT3-WT AML cells treated with AMG 925 (Fig. 1C). So, it is not surprising that inhibition of both kinases has been shown to cooperate in inhibiting AML cell growth (20). However, we hypothesize that CDK4-inhibiting activity of AMG 925 primarily acts through reducing frequency and/or expansion of mutants resistant to FLT3-inhibiting activity of the compound. Consistently, we have tried but failed to isolate AMG 925–resistant FLT3 mutations in MOLM13 and Mv4-11 under conditions that we used to isolate sorafenib-resistant mutations (our unpublished data). A potential advantage of AMG 925 over combining a FLT3 inhibitor with chemotherapy is that the CDK4-inhibiting activity of AMG 925 may be better tolerated based on the knock-out phenotype of these individual targets in mice (26, 27) and clinical trial results of the CDK4 inhibitor PD 0332991 (28). AMG 925 may also be efficacious as a treatment for patients with AML refractory to or relapsed from chemotherapy.

The sequence of treatments for a combination therapy of cancer can sometimes be critical to efficacy. For example, agents causing G1 arrest of the cell cycle are known to protect cancer cells from chemotherapies (29, 30). In contrast, it has been reported that CDK4 and FLT3 inhibitors, when added simultaneously to AML cells, acted cooperatively in inhibiting AML cell growth and inducing apoptosis (20). This result was confirmed in our experiments (our unpublished observations). Furthermore, we pretreated MOLM13 cells with CDK4 inhibitor PD 0332991 for 24 hours to arrest cells in G1 and then determined the effect on cell proliferation of FLT3 inhibition by sorafenib. We did not detect significant effect on the sensitivity of MOLM13 to sorafenib (our unpublished observations). However, we could not exclude the possibility that longer G1 arrest would eventually lead to decreased response to FLT3 inhibitors.

Analysis of relapsed AML in AC220-treated patients has confirmed two hot spots for resistance mutations in...
AMG 925, a FLT3/CDK4 Dual Inhibitor for Treating AML

Disclosure of Potential Conflicts of Interest
J.C. Medina and A. Kamb have ownership interest in Amgen, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Development of methodology: K. Keegan, C. Li, M. Ragains, J. Huard, L. Liu, J. Medina, K. Dai
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Keegan, C. Li, J. Ma, S. Coberly, D. Hollenback, M. Weidner, J. Huard, G. Alba, J. Ort, M.-C. Lo, S. Zhao, R. Ngo, A. Chen, T. Carlson
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K. Keegan, J. Ma, S. Coberly, J. Eksterowicz, J. Huard, J. Ort, S. Zhao, T. Carlson, D. Wickramasinghe, K. Dai
Writing, review, and/or revision of the manuscript: K. Keegan, M. Ragains, S. Coberly, D. Hollenback, J. Eksterowicz, J. Huard, G. Alba, M.-C. Lo, S. Zhao, L. Liu, T. Carlson, L.R. McGee, J. Medina, A. Kamb, D. Wickramasinghe, K. Dai
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Keegan, L. Liang, J. Huard, J. Medina, A. Kamb
Study supervision: K. Keegan, J. Ma, C. Queva, D. Wickramasinghe, K. Dai

Acknowledgments
The authors thank Tammy L. Bush and Michelle DuPont for carrying out the study in the Colo205 xenomouse tumor model. They also thank Wes Chang and Jay Dannos at Amgen Clinical Immunology for performing the flow cytometry and Tammy L. Bush and Gene Cutler for critical reading of the article.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 9, 2013; revised January 20, 2014; accepted February 4, 2014; published OnlineFirst February 13, 2014.

References


